0.17
+10.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharmala Biotech Holdings
Its shares trade on Canadian Securities Exchange under the ticker MDMA.CN. It has been listed since 11 January 2022. In the fiscal year to 31 August 2025, it reported revenue of C$605,498 and a net loss of C$2.2m. At that date it held total assets of C$3.4m and shareholders' equity of C$2.5m.
PharmAla Biotech Holdings, Inc. is a biotechnology company, which engages in the research, development, and manufacturing of MDXX class molecules, including MDMA. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2022-01-11. The firm is focused on the research, development, and manufacturing of methylenedioxy phenethylamines (MDXX)-class molecules, including methylenedioxy methamphetamine (MDMA). The firm is involved in sourcing finished clinical-grade LaNeo MDMA Drug Products in North America. Its drug active pharmaceutical ingredients (API) are encapsulated under GMP conditions and are available to entities who have Controlled Substances licenses, Section 56 Ministerial Exemptions, or Clinical Trial numbers within Canada. The company works with laboratories across Canada to develop processes for the supply of LaNeo MDMA and other MDXX substances.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 11 Jan 2022
- Website
- pharmala.ca ↗
Leadership
Pay as last reported
- Ms. Jodi ButtsIndependent Chairperson of the Board
- Mr. Nicholas KadyshPresident, Chief Executive Officer, Director, since 2021C$149,760
- Mr. Carmelo MarrelliChief Financial Officer, Corporate SecretaryC$75,142
- Dr. Farnoud KazemzadehChief Operating Officer
- Mr. Ali TaghvaChief Commercial Officer, Counsel
- Mr. Fraser MacdonaldIndependent DirectorC$750
- Mr. Kevin RoyIndependent Director
- Dr. Abdelmalik SlassiIndependent Director
- Mr. Perry TsergasIndependent DirectorC$3,299
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmala Biotech Holdings Inc focuses on MDXX class molecules including MDMA for clinical use.
- The company sources clinical-grade LaNeo MDMA Drug Products in North America.
- GMP conditions ensure encapsulated API availability for licensed entities in Canada.
Weaknesses
- The company's focus on MDMA limits its market scope to specific therapeutic areas.
- MDMA research requires strict regulatory approvals for clinical applications.
- Limited product diversity restricts revenue streams beyond MDXX molecules.
Opportunities
- Expanding clinical trials for MDMA-based therapies in North America.
- Growing demand for novel treatments in mental health care sectors.
- Collaborating with Canadian laboratories for MDXX substance development.
Threats
- Regulatory challenges for controlled substances like MDMA in global markets.
- Competition from other biotech firms developing similar compounds.
- Potential legal restrictions on MDMA research in international jurisdictions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.